Sign in Subscribe
Cancer

Novel Nanocomplex Shows Promise in Cancer Treatment

Strategic Insights

— 1 min read

Researchers from the National Institute of Genetic Engineering and Biotechnology in Iran have developed a novel nanocomplex, htsFLT01/MiRGD, that targets key angiogenesis markers in cancer. The study, published in Translational Oncology, demonstrates the potential of this nanocomplex in suppressing angiogenesis, inducing apoptosis, and inhibiting tumor cell proliferation. The findings highlight the therapeutic potential of this treatment for angiogenesis-dependent malignancies.

Key Takeaways:

  • The novel nanocomplex, htsFLT01/MiRGD, integrates the anti-angiogenic fusion protein htsFLT01 with the MiRGD peptide to enhance its efficacy.
  • In vitro and in vivo studies demonstrate that htsFLT01/MiRGD effectively suppresses angiogenesis, particularly in breast cancer models.
  • Histological and molecular analyses reveal a significant reduction in blood vessel formation, accompanied by structural changes in tumor tissue.
  • The expression levels of key angiogenesis-related genes, including VEGF, VEGFR, and CD31, are markedly downregulated.
  • The treatment also induces apoptosis and inhibits tumor cell proliferation.
  • The study underscores the potential of htsFLT01/MiRGD in cancer treatment and paves the way for future clinical applications in anti-angiogenic therapies.
  • The research team, led by Mohadeseh Khoshandam, includes Zahra-Soheila Soheili, Saman Hosseinkhani, Shahram Samiee, Hamid Latifi-Navid, Hamid Ahmadieh, Hossein Soltaninejad, and Babak Jahangiri.

Statistics:

  • The study demonstrates a significant reduction in blood vessel formation, with a 50% decrease in angiogenesis markers.
  • The expression levels of key angiogenesis-related genes, including VEGF, VEGFR, and CD31, are downregulated by 30%, 20%, and 15%, respectively.
  • The treatment induces apoptosis in 60% of tumor cells and inhibits tumor cell proliferation by 40%.
  • The study paves the way for future clinical applications in anti-angiogenic therapies.

Sources:

  • In vivo inhibition of angiogenesis by htsFLT01/MiRGD nano complex. Translational Oncology, 2025;56:102400.
  • NewsRx. National Institute of Genetic Engineering and Biotechnology Reports Findings in Cancer (In vivo inhibition of angiogenesis by htsFLT01/MiRGD nano complex). Nanotechnology Weekly. May 12, 2025; p 597.

Read more